NeoGenomics said last week it finalized an agreement to acquire GE Healthcare‘s (NYSE:GE) cancer diagnostic subsidiary Clarient for up to $275 million. GE Healthcare originally purchased Clarient for nearly double that price at approximately $587 million in 2011. NeoGenomics said the acquisition would allow it to broaden its cancer diagnostic testing offerings to both hospitals and physicians […]